Published in final edited form as:

Curr Hematol Malig Rep. 2018 June ; 13(3): 143–154. doi:10.1007/s11899-018-0454-x.

Frailty in Hematologic Malignancy

Thuy Koll¹ and Ashley E. Rosko²

¹Division of Geriatrics, University of Nebraska Medical Center, Omaha, NE

²Division of Hematology, The Ohio State University, Columbus, OH

Abstract

Purpose of Review—Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone, is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications.

Recent Findings—Dedicated geriatric assessment tools can aid the clinician in identifying geriatric syndromes such as frailty, resulting in improved prognostication to decrease morbidity and mortality. Frailty is not synonymous with individual performance status and is dynamic.

Summary—Establishing the patient goals, values and preferences is central to the consideration of malignant hematology decision process. Careful considerations of available data on the patient's prognosis based on estimated life expectancy, geriatric assessment data, and age-specific cancer mortality, with and without treatment, can reconcile the risks and benefits. Assessments of frailty, can aid the clinical feasibility and burden of the treatment to the patient and family in the context of each patient's unique needs.

Keywords

Hematologic malignancy; frailty; older adults; geriatric assessment

INTRODUCTION

Aging adults with hematologic malignancy are a growing demographic. The majority of hematologic malignancies are diagnosed in the older adult.(1) Few clinical trials are dedicated to aging adults specifically, resulting in limited data to gauge risk of chemotherapy toxicity or tolerability in older adults with hematologic malignancy. Clinical trial enrollment for aging adults with blood cancer is estimated to be 11% for adults >75 years old and 85% of all clinical trial participants are less than 65 years of age.(2) Without supporting data, clinicians are left to estimate the risk for chemotherapy toxicity based on clinical factors such as age, comorbidities and performance status. Yet these metrics alone are not a reliable estimate of life expectancy, functional capacity, or risk of treatment complications.(3, 4) Moreover, aging is heterogeneous and health status cannot be summarized by chronologic age alone. One of the greatest challenges in caring for older adults with hematologic

Corresponding Author: Ashley Rosko, MD, Division of Hematology, Department of Medicine, Ohio State University College of Medicine, A345 Starling Loving Hall, 320 W. 10th Avenue, Columbus, Ohio 43210, Phone: 614-293-7807, Fax: 614-293-7526, Ashley.Rosko@osumc.edu.

malignancy is to individualize therapy; balancing treatment efficacy with tolerability. As such, many oncologists have sought to work within the disciplines of oncology and geriatrics to optimize care for aging adults with cancer. Consequently, many tools and assessments from the discipline of geriatrics are being incorporated into routine oncology care. Here we provide an overview of our current understanding of frailty in older adults with hematological malignancy, as it applies to therapeutic decision, emerging therapies and outcomes for frailty in hematology.

FRAILITY IN GERIATRIC POPULATION

While there is a lack of consensus on the definition of frailty, most experts agree that frailty is measurable and is a clinical representation of the underlying dysregulation across multiple physiologic systems.(5) This dysregulation causes a decrease in the capacity to adapt and results in increased vulnerability to minimal stressors in older adults. Frailty is a result of age related physiological changes and is a state of diminishing reserve that can be exacerbated by diseases such as blood cancer. The physiological systems implicated in frailty include increase in inflammatory markers, decrease in hormones needed to maintain muscle mass and strength, and increase clotting activity, among others. (6–9) Frailty status is classified into three categories: non-frail (fit), pre-frail and frail. The pre-frail state signifies high risk of progression to a frail state. Importantly, frailty is dynamic, the progression from fit, pre-frail and frail is not always linear and is potentially reversible and amendable to interventions.(10) The clinical consequences of frailty include falls, worsening mobility, disability, hospitalizations, and death. (11)

Clinical management of frailty should focus on several notable factors: 1.) prevention, delay or reduction in severity of frailty and 2.) minimize the consequences of adverse outcomes in frail older adults.(12) A comprehensive Geriatric Assessment (GA) is a multidisciplinary in depth evaluation that can assess risk of morbidity and mortality in cancer patients and identify geriatric syndromes in an aging population(13, 14) (15) Frailty, is a geriatric syndrome and is considered the most common marker of adverse outcomes. (11) (16) Components of a GA may include the following domains of health: 1.) medical: evaluation of comorbidity, polypharmacy, sensory loss, and nutritional status; 2.) mental health: evaluation of cognition, depression, anxiety, and delirium 3.) functional status: assessment of activities of daily living (ADL), instrumental activities of daily living (IADL), mobility (physical performance), and falls 4.) social: evaluation of environment, resources, and social support/network. CGA's can improve health outcomes for frail older adults because it addresses abnormalities of multiple systems and the multifactorial etiologies that contribute to the frailty syndrome. (10, 17–20)

FRAILITY DISTINCT FROM COMORBIDITY AND DISABILITY

Comorbidity and disability are often correlated with frailty but these concepts are distinct. (21) Comorbidity is defined as the concurrent presence of two or more chronic diseases in an individual. Chronic diseases contribute to development of frailty and perhaps worsen the underlying decrease in reserve if not adequately managed. Disability is defined as difficulty or dependency in ADL. Disability may exacerbate comorbidity and frailty. (21) Geriatric

syndromes (e.g. osteoporosis, dementia, delirium) are common health conditions in the geriatric population and can also drive the development of the frailty syndrome.(12) There is a complex interaction between age-related physiological changes, comorbidity, geriatric syndromes such as frailty, blood cancer and treatments. There is heterogeneity in the aging process resulting in variable loss of reserve in multiple health domains. The likelihood of multiple chronic health conditions (comorbidity), geriatric syndromes specifically frailty increases with age and is compounded by unique psychosocial needs in the aging population. Geriatric assessment consists of validated tools to evaluate the physiologic reserve across multiple health domains affected by aging including social support and resources. Importantly, optimizing care for older adults with blood cancer is not dependent on a single factor such as age, disease, or frailty but rather dependent on the intersection of many common health related factors (Figure 1).

IDENTIFICATION OF FRAILITY IN CLINICAL PRACTICE

Frailty occurs in 15%–25% of community-dwelling older adults (≥ 65 years and older). (22) Clinicians caring for older adults recognize frailty as an important marker of poor outcomes. The integration of frailty measurements and clinical algorithms in subspecialty practice is evolving. (23) There are two major conceptual operationalization of frailty with proposed clinical measurement tools: frailty phenotype also known as Fried's frailty or Cardiovascular Health Study definition (11) and the Frailty Index. (24) Fried and colleagues used data from the Cardiovascular Health Study, to define frailty as a distinct clinical syndrome characterized by unexplained weight loss, low physical activity, weak grip, slow gait and self-reported exhaustion.(11) Individuals with three or more of these characteristics are considered frail, those with one or two characteristics are considered pre-frail, and those with none of the mentioned characteristics are considered non-frail. (11) Rockwood and colleagues proposes to look at health deficits and developed the Frailty Index based on CGA data. (24) The index is calculated by counting the number of health deficits including comorbidity, disability, cognitive impairment, psychosocial risk factors, and other geriatric syndromes. The Frailty Index represents the number of deficits over the total number of deficits considered. This model predict outcomes with greater precision due to inclusion of factors that likely contribute to poor outcomes such as comorbidity and disability. (25, 26) There are a number of other screening tools available to help clinicians identify those in need of further assessment including: FRAIL (Fatigue, Resistance, Ambulation, Illnesses, Loss of Weight), (27) Groningen Frailty Indicator, (28) and the Clinical Frailty Scale. (29) Frailty assessments, are commonplace in older adults, however it is necessary to denote that frailty is prevalent in childhood cancer survivors and associated with an increased risk of mortality in young hematopoietic cell transplant populations(30, 31).

FRAILITY IN HEMATOLOGICAL MALIGNANCIES

Oncologists are acutely aware of the impact of a cancer diagnosis on health status and wellbeing. This has been summarized in clinical terms as performance status and quantified dating back to the 1950's as the Karnofsky Performance Status (KPS) or alternatively using the Eastern Cooperative Oncology Group (ECOG) system. The system was developed to estimate a patients' tolerability of chemotherapy. The KPS is embedded into numerous

prognostication scoring systems such as the International Prognostic Index for non-Hodgkin Lymphoma (32) or for determining eligibility for allogeneic transplant for myelodysplastic syndrome.(33) In reality, it is unlikely that differences between KPS are clearly acknowledged in routine oncology care. Moreover, frailty is not synonymous with individual performance status. Frailty, a distinct clinical syndrome, is both dynamic and physiologic, where as traditional oncology metrics of performance status focus on functional status and scales of disability. Recently, frailty has been described in several cohort studies of older adults with hematologic malignancies (Table 1). In hematologic malignancy, there is a movement towards recognizing the clinical state of vulnerability and the role in treatment tolerance. There is not one method for identifying frailty. Frailty signifies a state of vulnerability to poor outcomes and there is heterogeneity in measurement of frailty in hematologic malignancies, with most studies using a GA to identify frailty. Individual GA domains can ascertain risk for chemotherapy toxicity in the oncology setting (34–36) and provide intervention targets to improve the ability of patients to undergo treatment for their cancer. Interventions to intervene and improve on frailty are many and are personalized to the deficits identified on the GA (Table 2). The interventions are designed to improve quality of life and to optimize overall health with aging. Deficits are variable in older adults and can be localized to only one domain or cross domains.

GA are underutilized in hematologic malignancy. In 2014, a systematic review evaluated use of a GA in hematologic malignancy where a minimum of 2 GA domains were included.(37) In summary, 18 publications from 15 studies were identified and concluded that geriatric deficits were associated with a shorter overall survival. In most studies, age and performance status lost their predictive value of mortality by multivariate analysis. Whereas comorbidity, physical function and nutritional status retained their predictive value. More recently, many studies have reported outcomes of the predictive value of GA domains in specific hematologic malignancy populations (Table 1). Here we provide our current understanding of frailty in older adults with common hematological malignancies.

Multiple Myeloma

Multiple Myeloma interest groups have sought to examine the predictive ability of geriatric assessment tools in clinical evaluation. The International Myeloma Working Group (IMWG) used a simplified GA tool based on age, comorbidities (Charlson Comorbidity Index), activities of daily living (ADL) and instrumental activities of daily living (IADL) for newly diagnosed older adults with multiple myeloma (38) The IMWG score was developed from patients registered on three prospective myeloma trials (n=889), which classified patients as fit (score = 0, 39%), intermediately fit (score = 1, 31%), and frail (score = 2, 30%). The IMWG frailty score was predictive of mortality, treatment discontinuation, and non-hematologic toxicities independent of treatment type, cytogenetics, or stage. Furthermore, other groups (39) have sought to examine prognostic scores combining end-organ function, performance status, frailty, and age in older adults with multiple myeloma. In multiple myeloma, the standard of care is autologous stem cell transplant (ASCT). The challenge for the myeloma community is standardizing the approach of fitness for ASCT. Balancing the toxicity and efficacy of ASCT is of particular relevance, given that transplant does not result in a cure. Major limitations for understanding the role of transplant in older adults is

hindered by past clinical trial designs based on age or vague descriptors of fitness for transplant.

Diffuse Large B-Cell Lymphoma (DLBCL)

Non-Hodgkin Lymphoma (NHL) is a disease of older adults with a median age of onset of 71 years. (40, 41) Evaluating treatment intensity in the aging adult with NHL is a priority given the possibility of curative intent chemotherapy. In the most common NHL, Diffuse large B-cell lymphoma (DLBCL) full-dose treatment is associated with improved outcomes but must be balanced by the tolerability and safety of the therapy.(42, 43) Tucci et al. demonstrated that a GA utilizing age, ADL, comorbidities and geriatric syndromes was better than clinical judgement in identifying patients fit for curative intent chemotherapy.(44) Prospective studies in DLBCL confirm un-fit and frail patients who received palliative vs. curative intent had similar outcomes.(45) Others have demonstrated in older adults with both aggressive and indolent NHL that geriatric factors such as malnutrition and frailty had predictive value for treatment discontinuation and frailty and hemoglobin were independent predictors of mortality.(46)

Chronic Lymphocytic Leukemia (CLL)

In CLL, many novel therapies and studies have been targeted specifically for older adults. Half of all patients diagnosed with CLL are 70 years and older. Many frontline strategies are available for older adults with CLL and several studies have focused on understanding the impact of end organ function and comorbidities on therapeutic outcomes. As an example, prognostic factors in older adults with CLL (median age 70) identified that 2 or more comorbidities, was associated with inferior PFS and OS.(47) The CLL9 trial implemented a comprehensive GA prior to fludarabine treatment to identify risk of treatment toxicity. Functional deficits using the objective Timed-up-and-go (TUG) and screening tests for dementia (DEMTECT) were associated with inferior survival.(48) Advances in care for older adults for CLL are a results of dedicated clinical trials for older adults with comorbidities leading to a better understanding of treatment tolerance and response.(49) Furthermore clinical trials designed for aging adults with CLL led to the approval of ground-breaking treatments, such as ibrutinib (50).

Acute Myelogenous Leukemia (AML)

Older adults with AML are among the most vulnerable patient population with the most diagnoses and deaths in those aged 65 years and older.(51) Older AML patients are more likely to have high risk cytogenetic features and overall poor outcomes.(52, 53) Moreover, the undertreatment (or no treatment) of older adults with AML is highly prevalent, where 60% of older adults in real-world analysis do not receive any therapy.(54) The goal of therapy for older adults with AML may be highly variable (curative vs. palliative). Geriatric assessments in AML have identified that patients who receive traditional cytotoxic chemotherapy with impaired functional performance and/or cognitive impairments have inferior overall survival.(55) Real-world analysis has demonstrated improved early mortality with intensive treatment over palliative treatment, independent of age or performance status at diagnosis.(56) Emerging personalized therapy for AML based on molecular abnormalities combined with physiologic age may transform our approach to older adults with AML.

Hematopoietic Cell Transplant (HCT)

Increasingly, many older adults are undergoing autologous and allogeneic HCT. Older adults account for 39% of patients 60 years and older undergo HCT, compared to <10% during the years 1999–2005. HCT is associated with a serious toll on health status in older adults with hematologic malignancies and understanding goals of care is imperative for the patient – physician relationship.

The proportion of allogeneic HCT recipients 70 years increased from 0.1 percent to 3.85 percent from 2000 to 2013 due to lower-intensity conditioning regimens and more accurate human leukocyte antigen typing.(57) Two-year overall survival significantly improved from 26 percent in 2000–2007 to 39% in 2008–2013. Similarly, two-year progression-free survival improved from 22 percent to 32 percent.(57) However, the two-year transplant-related mortality and complications such as graft-versus-host disease remain unchanged thus highlighting the need to improve patient selection and improvement in the transplant process to minimize toxicity and morbidity for older patients. (57)

The prevalence of frailty among young adult HCT survivors (8.4%) approach that seen in the older general population(10%).(58) The prevalence of frailty and pre-frailty are 28% and 51% respectively, in adults over age 50 prior to receiving allogeneic HCT.(59) In 203 patients with median age of 58 years who underwent allogeneic HCT, limitations in instrumental activities of daily living (HR 2.38; P<0.001), slow gait speed (HR 1.80; P=0.01), and low mental health by short-form-36 mental component (HR 1.67; P=0.01) pre-HCT were associated with worse survival (60). Allogeneic HCT patients are faced with many limitations that can have a negative impact of resuming important life activities post-HCT. Patients' goal in the first year after allogeneic HCT is to regain physical, mental and social function so they can participate in normal life. Addressing the impairment in these domains present an opportunity for the healthcare team to maximize the benefit of HCT (61).

Recent studies showed that older HCT survivors are more vulnerable to cognitive impairment.(62, 63) Specifically, at 3 years post-HCT, reduced-intensity HCT recipients scores declined significantly (P<0.003) for executive function, verbal fluency, and working memory compared to non-cancer controls (63). The ability to manage a complex medication regimen, enjoy a hobby, and return to prior social roles is more difficult with cognitive impairment (64). Given that allogeneic HCT survivors are at risk for accelerated aging, high burden of morbidity, and high prevalence of frailty and subclinical neurocognitive disorders such as mild cognitive impairment, screening for cognitive impairment is imperative to avoid further neurotoxicity that can lead to disability and loss of independence.

Autologous HCT is increasingly being implemented for older adults where 44% of patients who receive autologous HCT are > 60 years of age.(65) The number one indication is for multiple myeloma, a disease with rising incidence in older adults. Recently several studies have sought to examine frailty and geriatric assessment metrics in older adults undergoing autologous HCT. Recovery from autologous HCT in myeloma is related to functional performance status either by objective measures such as the short physical performance battery or IADL.(66, 67) Autologous transplant is also indicated in patients with lymphoma.

Sun et al retrospectively evaluated 170 patients with a median age of 72, 2-year PFS was - year 58% (95% [CI], 48%–67%) and overall survival was 65% (95% CI, 55%–74%).(68) Interestingly comorbidity scores were not predictive of NRM (7% NRM) further confirming the complexity and interdependence of a host of patient and disease factors on outcome. Implementing standardized metrics of the GA, including frailty, can identify individuals who are at greater risk for morbidity following autologous HCT.

DECISION MAKING FOR OLDER ADULTS WITH HEMATOLOGIC MALIGNANCY

Establishing the patient and family treatment goals (i.e. life-prolongation, cure of disease or symptom management), values and preferences (i.e. functional independence, quality of life) is central to the consideration of malignant hematology decision process. This is followed by careful considerations of available data on the patient's prognosis based on estimated remaining life expectancy and age-specific cancer mortality with and without treatment. Finally, together with patient and family, the physician should help reconcile the treatment options risks and benefits with patient's treatment goals, values and preferences. GA can also inform cancer management decision by assessing clinical feasibility (tolerance) and burden of the treatment to the patient and family in the context of each patient unique psychosocial needs. Once shared-decision is made regarding a treatment, implementation of appropriate supportive care with the goal to maintain health, function and quality of life is crucial in older adults. The Multinational Association for Supportive Care in Cancer defines supportive care in cancer as: "supportive care in cancer is the prevention and management of the adverse effects of cancer and its treatment. This includes management of physical and psychological symptoms and side effects across the continuum of the cancer experience from diagnosis through treatment to post-treatment care. Supportive care aims to improve the quality of rehabilitation, secondary cancer prevention, survivorship, and end-of-life care." (69) A hematologic malignancy diagnosis abruptly changes health status. In many cases, by treating the underlying illness patients can and do improve allowing for potential treatment or transplant options that were not considered at diagnosis. Supportive care management will vary within the continuum of the disease.

Here we propose an integrated geriatric supportive care strategy starting at the time of diagnosis and throughout the continuum of care (Figure 2). Treatment for hematological malignancies can worsen underlying chronic health conditions, and may potentiate functional dependence and geriatric syndromes such as depression, malnutrition and falls. Supportive care management of older patients with hematologic malignancies needs an approach that systematically assesses health status, functional abilities, and evaluation of geriatric syndromes unique to the individual. There is an opportunity to intervene with supportive care strategies at all time points along the cancer care continuum using validated GA tools. There is a need for a proactive approach to partner with geriatricians, palliative care, primary care physicians, physical therapy, occupational therapy, dieticians and social work to leverage their expertise to improve outcomes for older adults. Finally, active participation and engagement of patients and family to increase self-efficacy in self-management of their health and decision-making is important to execute such a program.

CONCLUSIONS

Identifying frailty in patients with hematologic malignancy is relevant to both optimize best therapy and quality of life in older adults. Barriers to incorporate frailty metrics into best clinical practice are multifactorial. Older adults in general, including those with hematologic malignancy(70), are under enrolled and understudied in clinical trials(2). Requiring aspects of frailty in clinical trial design are necessary to advance the care of aging adults. Moreover including translational science in the biology of aging, or geroscience, is important to field of geriatric hematology/oncology research(71). The need for assessments of physiologic age is increasingly necessary in the era of cellular therapy and intensive treatment such as transplant. These efforts to advance the biology of aging with geriatric research will improve the disease course and ideally mitigate treatment toxicity. The reviewed literature demonstrates the interdependence of health factors on treatment outcomes with aging. No single individual factor will determine health outcomes with aging, rather identifying patients who are vulnerable to toxicity and intervening on those factors can improve outcomes. In summary, the following key concepts can help guide the clinician when addressing frailty in hematologic malignancy.

- Aging is heterogeneous and health status cannot be summarized by chronologic age alone.
- Frailty is dynamic. A hematologic malignancy diagnosis abruptly changes health status. In many cases, by treating the underlying illness patients can and do improve allowing for potential treatment or transplant options that were not considered at diagnosis.
- A Geriatric Assessment is an established tool to identify frailty and assess for etiologies contributing to the frailty syndrome.
- Objective measures of health status using geriatric assessments partnered with subjective measures are better than clinical judgement alone.
- Partner with geriatricians or specialized care teams dedicated to aging adults to optimize health factors with aging.
- Preserving quality of life is meaningful in the older adults. Shared-decision making is made to establish goals and expectations regarding prognosis. Implementation of appropriate supportive care with the goal to maintain health, function and quality of life is crucial in older adults.

References

1. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. *Brit J Cancer*. 2011; 105(11):1684–92. [PubMed: 22045184]
2. Bindu Kanapuru HS, Myers Adrian, Beaver Julia A, Kwitkowski Virginia Elaine, Farrell Ann T, Pazdur Richard. Enrollment of Older Adults in Clinical Trials Evaluating Patients with Hematologic Malignancies - the Food and Drug Administration (FDA) Experience. *American Society of Hematology (ASH) Abstract 861*. Dec.2017

3. Wedding U, Rohrig B, Klippstein A, Pientka L, Hoffken K. Age severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. *Journal of cancer research and clinical oncology*. 2007; 133(12):945–50. [PubMed: 17534661]
4. Hurria A. Communicating treatment options to older patients: challenges and opportunities. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2012; 10(9):1174–6. [PubMed: 22956814]
5. Rodriguez-Manas L, Fearnt C, Mann G, Vina J, Chatterji S, Chodzko-Zajko W, et al. Searching for an operational definition of frailty: a Delphi method based consensus statement: the frailty operative definition-consensus conference project. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2013; 68(1):62–7.
6. Fried LP, Xue QL, Cappola AR, Ferrucci L, Chaves P, Varadhan R, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2009; 64(10):1049–57.
7. Liu LK, Lee WJ, Liu CL, Chen LY, Lin MH, Peng LN, et al. Age-related skeletal muscle mass loss and physical performance in Taiwan: implications to diagnostic strategy of sarcopenia in Asia. *Geriatrics & gerontology international*. 2013; 13(4):964–71. [PubMed: 23452090]
8. Newman AB, Gottdiener JS, McBurnie MA, Hirsch CH, Kop WJ, Tracy R, et al. Associations of subclinical cardiovascular disease with frailty. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2001; 56(3):M158–66.
9. Phan HM, Alpert JS, Fain M. Frailty, inflammation, and cardiovascular disease: evidence of a connection. *The American journal of geriatric cardiology*. 2008; 17(2):101–7. [PubMed: 18326951]
10. Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, et al. Frailty consensus: a call to action. *Journal of the American Medical Directors Association*. 2013; 14(6):392–7. [PubMed: 23764209]
11. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2001; 56(3):M146–56.
12. Chen X, Mao G, Leng SX. Frailty syndrome: an overview. *Clin Interv Aging*. 2014; 9:433–41. [PubMed: 24672230]
13. Pal SK, Katheria V, Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. *CA Cancer J Clin*. 2010; 60(2):120–32. [PubMed: 20173172]
14. Rodin MB, Mohile SG. A practical approach to geriatric assessment in oncology. *J Clin Oncol*. 2007; 25(14):1936–44. [PubMed: 17488994]
15. Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. *The Lancet Oncology*. 2012; 13(10):e437–44. [PubMed: 23026829]
16. Bandeen-Roche K, Xue QL, Ferrucci L, Walston J, Guralnik JM, Chaves P, et al. Phenotype of frailty: characterization in the women's health and aging studies. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2006; 61(3):262–6.
17. Kojima G, Bell C, Tamura B, Inaba M, Lubimir K, Blanchette PL, et al. Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. *Journal of the American Medical Directors Association*. 2012; 13(9):818.e11–5.
18. Morley JE, Argiles JM, Evans WJ, Bhasin S, Cella D, Deutz NE, et al. Nutritional recommendations for the management of sarcopenia. *Journal of the American Medical Directors Association*. 2010; 11(6):391–6. [PubMed: 20627179]
19. Muir SW, Montero-Odasso M. Effect of vitamin D supplementation on muscle strength, gait and balance in older adults: a systematic review and meta-analysis. *Journal of the American Geriatrics Society*. 2011; 59(12):2291–300. [PubMed: 22188076]
20. Theou O, Stathokostas L, Roland KP, Jakobi JM, Patterson C, Vandervoort AA, et al. The effectiveness of exercise interventions for the management of frailty: a systematic review. *Journal of aging research*. 2011; 2011:569194. [PubMed: 21584244]

21. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2004; 59(3):255–63.
22. Bandeen-Roche K, Seplaki CL, Huang J, Buta B, Kalyani RR, Varadhan R, et al. Frailty in Older Adults: A Nationally Representative Profile in the United States. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2015; 70(11):1427–34.
23. Walston J, Robinson TN, Ziemann S, McFarland F, Carpenter CR, Althoff KN, et al. Integrating Frailty Research into the Medical Specialties-Report from a U13 Conference. *Journal of the American Geriatrics Society*. 2017; 65(10):2134–9. [PubMed: 28422280]
24. Jones DM, Song X, Rockwood K. Operationalizing a frailty index from a standardized comprehensive geriatric assessment. *Journal of the American Geriatrics Society*. 2004; 52(11):1929–33. [PubMed: 15507074]
25. Rockwood K, Mitnitski A. Frailty defined by deficit accumulation and geriatric medicine defined by frailty. *Clinics in geriatric medicine*. 2011; 27(1):17–26. [PubMed: 21093719]
26. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. *BMC geriatrics*. 2008; 8:24. [PubMed: 18826625]
27. Abellan van Kan G, Rolland Y, Bergman H, Morley JE, Kritchevsky SB, Vellas B. The I.A.N.A Task Force on frailty assessment of older people in clinical practice. *J Nutr Health Aging*. 2008; 12(1):29–37. [PubMed: 18165842]
28. Peters LL, Boter H, Buskens E, Slaets JP. Measurement properties of the Groningen Frailty Indicator in home-dwelling and institutionalized elderly people. *Journal of the American Medical Directors Association*. 2012; 13(6):546–51. [PubMed: 22579590]
29. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2005; 173(5):489–95.
30. Ness KK, Krull KR, Jones KE, Mulrooney DA, Armstrong GT, Green DM, et al. Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study. *J Clin Oncol*. 2013; 31(36):4496–503. [PubMed: 24248696]
31. Arora M, Sun CL, Ness KK, Teh JB, Wu J, Francisco L, et al. Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow Transplant Survivor Study. *JAMA oncology*. 2016; 2(10):1277–86. [PubMed: 27254472]
32. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. *J Clin Oncol*. 2010; 28(14):2373–80. [PubMed: 20385988]
33. Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcarcel D, et al. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. *J Clin Oncol*. 2016; 34(16):1864–71. [PubMed: 27044940]
34. Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, et al. Developing a cancer-specific geriatric assessment: a feasibility study. *Cancer*. 2005; 104(9):1998–2005. [PubMed: 16206252]
35. Hurria A, Cirincione CT, Muss HB, Kornblith AB, Barry W, Artz AS, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011; 29(10):1290–6. [PubMed: 21357782]
36. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. *Blood*.
37. Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. *Leukemia research*. 2014; 38(3):275–83. [PubMed: 24439052]
38. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. *Blood*. 2015; 125(13):2068–74. [PubMed: 25628469]

39. Engelhardt M, Domm AS, Dold SM, Ihorst G, Reinhardt H, Zober A, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. *Haematologica*. 2017; 102(5):910–21. [PubMed: 28154088]
40. American Cancer Society. Cancer Statistics Center. Atlanta, GA: American Cancer Society; 2017.
41. Surveillance E. End Results (SEER) Program. Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. 2017
42. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol*. 2005; 23(18):4117–26. [PubMed: 15867204]
43. Marchesi F, Cenfra N, Altomare L, Dessanti ML, Mecarocci S, Cerchiara E, et al. A retrospective study on 73 elderly patients (≥ 75 years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment. *Journal of geriatric oncology*. 2013; 4(3):242–8. [PubMed: 24070462]
44. Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. *Cancer*. 2009; 115(19):4547–53. [PubMed: 19562776]
45. Tucci A, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F, et al. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). *Leukemia & lymphoma*. 2015; 56(4):921–6. [PubMed: 25110825]
46. Aaldriks AA, Giltay EJ, Nortier JW, van der Geest LG, Tanis BC, Ypma P, et al. Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma. *Leukemia & lymphoma*. 2015; 56(4):927–35. [PubMed: 24956143]
47. Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. *Blood*. 2009; 114(16):3382–91. [PubMed: 19605849]
48. Goede V, Bahlo J, Chataline V, Eichhorst B, Durig J, Stilgenbauer S, et al. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. *Leuk Lymphoma*. 2016; 57(4):789–96. [PubMed: 26377031]
49. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *The New England journal of medicine*. 2014; 370(12):1101–10. [PubMed: 24401022]
50. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. *The New England journal of medicine*. 2015; 373(25):2425–37. [PubMed: 26639149]
51. Howlader, NNA. Krapcho, M. Miller, D. Bishop, K. Kosary, CL. Yu, M. Ruhl, J. Tatalovich, Z. Mariotto, A. Lewis, DR. Chen, HS. Feuer, EJ., Cronin, KA., editors. SEER Cancer Statistics Review, 1975–2014. National Cancer Institute; Bethesda, MD: https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, January 2018
52. Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Dohner K, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. *Blood*. 2006; 108(10):3280–8. [PubMed: 16840728]
53. Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, Vardiman JW, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. *Blood*. 2006; 108(1):63–73. [PubMed: 16522815]
54. Medeiros BC, Satram-Hoang S, Hurst D, Hoang KQ, Momin F, Reyes C. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. *Annals of hematology*. 2015; 94(7):1127–38. [PubMed: 25791241]

55. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. *Blood*. 2013; 121(21):4287–94. [PubMed: 23550038]
56. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. *Blood*. 2009; 113(18):4179–87. [PubMed: 19008455]
57. Muffy L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation (HCT) in patients age 70 years and older: a CIBMTR study of trends and outcomes. *Biology of Blood and Marrow Transplantation*. 2016; 22(3):S68–S9.
58. Arora M, Sun C-L, Ness KK, Teh JB, Wu J, Francisco L, et al. Physiologic frailty in nonelderly hematopoietic cell transplantation patients: results from the bone marrow transplant survivor study. *JAMA oncology*. 2016; 2(10):1277–86. [PubMed: 27254472]
59. Muffy LS, Boulukos M, Swanson K, Kocherginsky M, del Cerro P, Schroeder L, et al. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. *Biology of Blood and Marrow Transplantation*. 2013; 19(3):429–34. [PubMed: 23160006]
60. Muffy LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. *Haematologica*. 2014; 99(8):1373–9. [PubMed: 24816237]
61. Johansson E, Larsen J, Schempp T, Jonsson L, Winterling J. Patients' goals related to health and function in the first 13 months after allogeneic stem cell transplantation. *Supportive Care in Cancer*. 2012; 20(9):2025–32. [PubMed: 22081115]
62. Hoogland AI, Nelson AM, Small BJ, Hyland KA, Gonzalez BD, Booth-Jones M, et al. The role of age in neurocognitive functioning among adult allogeneic hematopoietic cell transplant recipients. *Biology of Blood and Marrow Transplantation*. 2017; 23(11):1974–9. [PubMed: 28797784]
63. Sharafeldin N, Bosworth A, Patel SK, Chen Y, Morse E, Mather M, et al. Cognitive Functioning After Hematopoietic Cell Transplantation for Hematologic Malignancy: Results From a Prospective Longitudinal Study. *Journal of Clinical Oncology*. 2017 JCO.2017.74.270.
64. Myers, JS., editor. *Seminars in oncology nursing*. Elsevier; 2013. Cancer-and chemotherapy-related cognitive changes: The patient experience.
65. Pasquini, MC. ZXCuaohsctCSS. 2015. Available at: <http://www.cibmtr.org>
66. Rosko AE, Hofmeister CC, Efebera YA, Benson DM, Sborov DW, Jaglowski S, et al. Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients. *Blood*. 2015; 126(23)
67. Wildes TM, Tew WP, Maggiore RJ, Edwards BJA, Cohen HJ, Smith DD, et al. Association of geriatric assessment factors with falls in older adults initiating chemotherapy. *J Clin Oncol*. 2015; 33(15)
68. Sun L, Li SL, Armand P, Chen YB, DeFilipp Z. Safety and efficacy of autologous stem cell transplantation in lymphoma patients in their 70s. *J Clin Oncol*. 2017; 35
69. Multinational Association for Supportive Care in Cancer. What is MASCC?. [05/03/2016]. Available from: <http://www.mascc.org/about-mascc>
70. Cherubini A, Pierri F, Gasperini B, Zengarini E, Cerenzia A, Bonifacio E, et al. Are ongoing trials on hematologic malignancies still excluding older subjects? *Haematologica*. 2013; 98(7):997–1000. [PubMed: 23813644]
71. Sierra F. The Emergence of Geroscience as an Interdisciplinary Approach to the Enhancement of Health Span and Life Span. *Cold Spring Harbor perspectives in medicine*. 2016; 6(4):a025163. [PubMed: 26931460]

Figure 1.

Complex interaction between age-related physiological changes, comorbidity, geriatric syndromes such as frailty, and hematologic malignancy. Here we demonstrate Overlapping geriatric domains of nutrition, polypharmacy, socio-demographics, comorbidity, functional status, Psychosocial status and geriatric syndromes

Figure 2.
An integrated geriatric supportive care strategy

Key components:

- Supportive care plans adapted to patient's needs and preemptive referral to specialized care based on risk.
- Screening and implementation of interventions across survivorship continuum using GA tools.
- Active participation and engagement of patients and family/caregivers.

Key elements of interventions:

- Education and support for physical activity
- Nutrition optimization
- Minimize polypharmacy
- Address geriatric syndromes (depression, falls)
- Manage comorbidities

Table 1

Predictors and outcomes of geriatric assessment and frailty studies in hematologic malignancies.

Author	Year of pub	Number of patients	Cancer type(s) Age [mean, median years]	Assessment	Patient Characteristics	Outcome	Conclusions
Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)							
Klepin et al. (1)	2013	N=70	AML 70 years	GA	Cognitive impairment: HR 2.5 [1.2,5.5] Impaired physical function: HR 2.2 [1.1,4.6]	Survival	Survival at 30 days was inferior for patients with impairment in cognition and physical function.
Deschler et al. (2)	2013	N=195	AML and MDS 71 years	GA and Quality of Life	Impairment in activities of daily living (ADL): HR 2.10 [1.13,3.89] Quality of life (QOL)-fatigue: HR 2.09 [1.17,3.71] KPS <80%: HR 2.45 [1.23,4.87]	Survival	Survival was inferior for patients with impairment in ADL and QOL-fatigue score of 50.
Sherman et al. (3)	2013	N=368	AML 65 years (40.6%)	Quality of Life Comorbidity	Comorbidity: HR 1.92 [1.18,3.11] Difficulty with strenuous activity: HR 2.18 [1.19,4.0] Reports of pain: HR 2.17 [1.19,3.97]	Survival	Patients with higher baseline comorbidity score, difficulty strenuous activity and pain had inferior survival.
Fega et al. (4)	2015	N=114	MDS 73 years	Quality of Life Clinical-pathologic data	Low serum albumin: HR 2.3 [1.06,5.14] Ease of taking a long walk: HR 0.44 [0.23,0.90]	Survival	Low serum albumin and ease of taking a long walk added important prognostic information to survival.
Buckstein et al. (5)	2016	N=445	MDS 71 years	Rockwood Frailty Scale Comorbidity (Charlson comorbidity score)	Frailty: HR 2.7 [1.7,4.2] Comorbidity: HR 1.8 [1.1,2.8]	Survival	Survival was significantly shorter for patients with higher frailty and comorbidity scores.
Klepin et al. (6)	2016	N=49	AML 70 years	GA	Baseline depression and cognitive impairment	Decline in physical function (SPPB)	Patients with depressive symptoms before and during chemotherapy had greater decline in SPPB scores at baseline and on follow up.
Diffuse Large B-Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (CLL)							

Author	Year of pub	Number of patients	Cancer type(s) Age [mean, median years]	Assessment	Patient Characteristics	Outcome	Conclusions
Merli et al. (7)	2014	N=99	DLBCL 78 years	GA	GA "frail": HR 3.09 [2.20,4.33]	Survival	Survival was inferior for frail patients even if they were treated with rituximab containing combination chemotherapy.
Aaldriks et al. (8)	2015	N=44	DLBCL 78 years	GA, Groningen Frailty Indicator (GFI), and laboratory markers	GFI: OR 9.2 [1.5, 55.8], HR 2.6 [1.1,6.1]	Treatment withdrawal Survival	Abnormal nutrition, GFI scores and low hemoglobin level were associated with not being able to complete intended chemotherapy. Patients with frailty classification on GFI and low hemoglobin had inferior survival.
Tucci et al. (9)	2015	N=173	DLBCL 77 years	GA International Prognostic Index (IPI)	IPI: HR 4.60 [1.35,15.64] GA: 3.69 [1.09,12.51]	Survival in "fit", "unfit" and "frail"	Curative treatment in unfit patients showed a clear trend towards better 2 - year overall survival (75% vs. 45%) but not in frail patients (44% vs. 39%). IPI and CGA is associated with survival.
Yoshida et al. (10)	2016	N=135	DLBCL 72 years	GA	GA "unfit": HR 2.23 [18,4,22]	Survival	Survival was inferior for patients with ADL impairment and "unfit" classification on CGA.
Multiple Myeloma							
Engelhardt et al. (11)	2017	N=801	Myeloma 63 years	revised Myeloma Comorbidity Index	Index >6 "frail": OS 1.2 years Index 4-6 "intermediate fit": OS 4.4 years Index 3 "fit": OS 10.1 years	Survival	fit (revised Myeloma Comorbidity Index of 1-3): OS 10.1 years intermediate-fit (revised Myeloma Comorbidity Index of 4-6): OS 4.4 years frail (revised Myeloma Comorbidity Index of >6) 1.2 years

Author	Year of pub	Number of patients	Cancer type(s) Age [mean, median years]	Assessment	Patient Characteristics	Outcome	Conclusions
Fiala et al. (¹²)	2017	N=340	Myeloma 75 years	Frailty index (FI)	Lowest tertile of FI 48 months vs 23 months for the highest tertile of FI	Survival	Each 10% increase in FI was associated with a 15% increased risk of death.
Li et al. (¹³)	2017	N=12,547	Myeloma 66 years	Frailty defined as poor claims—based disability status (PDS)	PDS frail vs fit: 3-year OS: 34% vs 61% (P= 0.01) who began first line therapy	Survival	Frail patients were older, had higher comorbidity and worse OS.
Nathwani et al. (¹⁴)	2017	N=210	Myeloma 72 years	Modified GA including Palumbo frailty score	Frailty score influences provider decision making 50% of the time	Treatment decision	Preliminary data support feasibility, usability and acceptability of modified GA.
Schutz et al. (¹⁵)	2017	N=150	Myeloma 77 years	Edmonton frailty score	Frailty status: OR 8.2 [1.9,34]	Early mortality	Frailty was associated with early death. Frailty criteria independently associated with death include: incontinence, polypharmacy, and previous hospital admissions
Hematologic Malignancies (Mixed)							
Velghe et al. (¹⁶)	2016	N=59	Hematologic malignancies	Hand grip strength (HGS)	HGS: AUC 0.800 (women) and 0.847 (men)	Abnormal GA	HGS was associated with concurrent abnormal CGA.
Hsieh et al. (¹⁷)	2016	N=235	Hematologic malignancies 78 years	Cognition by Montreal Cognitive Assessment (MOCA)-delayed recall and Clock in Box (CIB)	Cognitive impairment per CIB: OR 1.89 [1.07,3.34] MOCA delayed recall: OR 1.86 [1.02,3.40]	Pre-frail or frailty status	Cognitive impairment likely contributes to overall frailty status.
Teran et al. (¹⁸)	2017	N=32	Hematologic malignancies 81 years	GA G8 screen	Frailty score influences therapeutic decisions in 34% of the time	Initial therapeutic decisions	Treatment was adjusted in 34% of the cases because of frailty score.
Hematopoietic Cell Transplantation (HCT)							
Rosko et al. (¹⁹)	2015	N=55	Myeloma autologous HCT 61 years	GA <i>p16 mRNA</i>	Objective physical function (P=0.04) Self-reported physical function (P=0.05)	Length of stay	Objective and subject measures of physical function may help identify older adults at high risk for adverse outcomes after autologous HCT.

Author	Year of pub	Number of patients	Cancer type(s) Age [mean, median years]	Assessment	Patient Characteristics	Outcome	Conclusions
Wildes et al. (20)	2015	N=40	Myeloma 69.5 years	GA	Age (P=0.047) Slow time on TUG (P=0.048) CCI 1 (P=0.002) Poor baseline QOL (P=0.006)	Not eligible for autologous HCT	In addition to age and comorbidity, TUG and patient self-reported quality of life were associated with autologous HCT eligibility.
Muffy et al. (21)	2014	N=203	Hematologic malignancies Allogeneic HCT 58 years	GA Phenotypic frailty Hematopoietic Cell Transplant Comorbidity Index (HCT-CI)	Limitations in IADLs: HR 2.38 [1.59,3.56] Slow walk speed HR: 1.80 [1.14,2.83] High HCT-CI: HR 1.56 [1.07,2.28] Low mental function: HR 1.67 [1.12-2.48] Elevated C reactive protein: HR 2.51 [1.54,4.09]	Survival	Patients with limitations in IADLs, slow walk speed, high HCT-CI, low mental function, and elevated serum CRP had inferior survival. This association is more pronounced in the cohort 60 and older. IADL adds prognostic significance to HCT-CI
Arora et al. (22)	2015	N=96	Autologous and Allogeneic HCT	GA Phenotypic frailty	Time from HCT: OR 3.7 [1.9,7.2] Pre-HCT employment status (retirement): OR 7.3 [1.2-46.2] Pre-HCT medical leave/disabled: OR 11.2 [1.8,67.7] Limitations in social activities: OR 1.04 [1.01, 1.07] Allogeneic HCT: OR 3.1 [0.9,10.2]	Frailty status	The prevalence of frailty was 8% at baseline and increased to 39% by 6 months. This study identifies factors associated with frailty after HCT.
Arora et al. (23)	2016	N=998	Autologous and Allogeneic HCT 42.5 years	Phenotypic frailty	Frailty status: OR 2.76 [1.7, 4.4]	Survival	HCT survivors were 8.4 times more likely to be frail than siblings. Prevalence of frailty among young adult HCT survivors (8.4%) approach that seen in the elderly general population (10%).

GA: Geriatric assessment
 ADL: Activities of daily living
 KPS: Karnofsky performance status
 IADL: Instrumental activities of daily living
 SPPB: Short Physical Performance
 TUG: Timed Up and Go
 OR: Odds Ratio
 HR: Hazard Ratio
 AUC: Area under the curve
 OS: Overall survival

- ¹ Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. *Blood*. 2013;121(21):4287-94.
- ² Deschler B, Ihorst G, Platzbecker U, Gemming U, März E, de Figueiredo M, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. *Haematologica*. 2013;98(2):208-16.
- ³ Sherman AE, Motyckova G, Fega KR, DeAngelo DJ, Abel GA, Steensma D, et al. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. *Leukemia research*. 2013;37(9):998-1003.
- ⁴ Fega KR, Abel GA, Motyckova G, Sherman AE, DeAngelo DJ, Steensma DP, et al. Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. *Journal of geriatric oncology*. 2015;6(4):288-98.
- ⁵ Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KW, et al. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. *British journal of haematology*. 2016;174(1):88-101.
- ⁶ Klepin HD, Tooze JA, Pardee TS, Ellis LR, Berenzon D, Mihalko SL, et al. Effect of intensive chemotherapy on physical, cognitive, and emotional health of older adults with acute myeloid leukemia. *Journal of the American Geriatrics Society*. 2016;64(10):1988-95.
- ⁷ Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Ferrari A, et al. Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. *Leukemia & lymphoma*. 2014;55(1):38-43.
- ⁸ Aldriks AA, Giltay EJ, Nortier JW, van der Geest LG, Tanis BC, Ypma P, et al. Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma. *Leukemia & lymphoma*. 2015;56(4):927-35.
- ⁹ Tucci A, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F, et al. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). *Leukemia & lymphoma*. 2015;56(4):921-6.
- ¹⁰ Yoshida M, Nakao T, Horiuchi M, Ueda H, Hagihara K, Kanashima H, et al. Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for 'unfit' patients classified by comprehensive geriatric assessment. *European journal of haematology*. 2016;96(4):409-16.
- ¹¹ Engelhardt M, Domm A-S, Dold SM, Ihorst G, Reinhardt H, Zober A, et al. A concise revised myeloma comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. *haematologica*. 2017;haematol. 2016.162693.
- ¹² Fiala MA, Guerard EJ, Schroeder MA, Stockert-Goldstein K, Vij R, Wildes TM. Development and validation of a Medicare health outcomes survey (MHOS) frailty index in multiple myeloma (MM). *American Society of Clinical Oncology*; 2017.
- ¹³ Li S, Natwick T, Liu J, Morrison VA, Vidito S, Werther W, et al. Mortality by Frailty Status as Defined by a Claims-Based Disability Status in Elderly Patients Newly Diagnosed with Multiple Myeloma in the United States. *Clinical Lymphoma, Myeloma and Leukemia*. 2017;17(1):e52-e3.

- ¹⁴ Nathwani N, Mohile SG, Lipe B, Carig K, DiGiovanni L, Davis A, et al. Integrating a touchscreen-based brief geriatric assessment in older adults with multiple myeloma. *American Society of Clinical Oncology*; 2017.
- ¹⁵ Schutz N, Smetniansky M, Fantl D, Otero V, editors. *FRAILTY AND MORTALITY IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA. HAEMATOLOGICA*; 2017: FERRATA STORTI FOUNDATION VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY.
- ¹⁶ Velghe A, De Buyser S, Noens L, Demuyneck R, Petrovic M. Hand grip strength as a screening tool for frailty in older patients with haematological malignancies. *Acta Clinica Belgica*. 2016;71(4): 227-30.
- ¹⁷ Hsieh TT, Condron NB, Stone RM, Soiffer RJ, Abel GA. Measurement and Prevalence of Cognitive Impairment in Older Patients with Hematologic Malignancies. *Blood*. 2016;128(22):689-.
- ¹⁸ Teran C, Hormigo A, Cordoba R, Jarana M, Perez M, Plaza C, et al., editors. *THE THERAPEUTIC UTILITY OF A SYSTEMATIC PROTOCOL FOR GERIATRIC ASSESSMENT IN ONCOHEMATOLOGIC PATIENTS. HAEMATOLOGICA*; 2017: FERRATA STORTI FOUNDATION VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY.
- ¹⁹ Rosko AE, Hofmeister CC, Efebera YA, Benson DM, Sborov DW, Jaglowski S, et al. Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients. *Am Soc Hematology*; 2015.
- ²⁰ Wildes TM, Tuchman SA, Depp B, Chen L, Stockert-Goldstein K, Vij R, et al. Geriatric assessment (GA) and eligibility for autologous stem cell transplant (ASCT) in older adults with newly diagnosed multiple myeloma (MM). *Journal of Clinical Oncology*. 2015;33(15).
- ²¹ Muffly LS, Koehriginsky M, Stock W, Chu Q, Bishop MR, Godley LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. *Haematologica*. 2014;99(8):1373-9.
- ²² Arora M, Bhatia S, DeFor TE, Nayyar M, Belete H, Lund T, et al. Impact of Frailty on Hematopoietic Cell on Early Transplant Outcomes in Older Recipients. *Am Soc Hematology*; 2015.
- ²³ Arora M, Sun C-L, Ness KK, Teh JB, Wu J, Francisco L, et al. Physiologic frailty in nonelderly hematopoietic cell transplantation patients: results from the bone marrow transplant survivor study. *JAMA oncology*. 2016;2(10):1277-86.

Table 2

Interventions for Geriatric Syndromes

Domains	Common Tools	Interventions
Function	ADL,IADL TUG, 4 meter walk, SPPB, functional gait assessment, 5 times sit to stand, Fall risk assessment, handgrip	Physical therapy, occupational therapy, aquatic therapy, durable medical equipment, falls education, home-safety evaluations (e.g. grab bars), medications for chemotherapy induced neuropathy, compression stockings for chemotherapy induced lower extremity edema, drivers rehabilitation
Social Support and Function	Illness specific subscales of social support (ISSS), MOS-SSS, MOS-SAS	Personal medical alert devices, medication assistance for financial restrictions, implement advance directives, arrange for transportation for medical appointments, home health care arrangements (nursing, home health aid) evaluation of elder mistreatment, respite needs, partnership with local aging agencies for community resources (e.g. silver sneakers, eldercare)
Cognition	Mini-mental state examination, MOCA, BOMC, DemTect, mini-COG, SLUMS, Clock-drawing test	Medications for memory loss, if hearing loss: hearing aids for improved sensorium, identification of chemotherapy induced cognitive impairment and longitudinal assessment
Psychologic	Geriatric depression scale Mental health inventory Mini GDS	Medications for anxiety, depression, coping and support, sleep recommendations, referral for psychology or psychiatry input
Nutritional status	Mini-nutritional assessment, anthropometrics	Dental evaluation for dentures, medications for appetite stimulants, improved medication control of nausea, calorie/protein/fluid recommendations
Polypharmacy	Beers criteria, >5 medications	Deprescribe, discontinue supplements/herbal remedies, provide education on drug-drug duplicates and interactions, provide safe alternatives for drugs that should be avoided in older adults, pillbox use and reconciliation